开云app官网登录入口网页版-官方正版

#三阴性#

205篇内容 | 3182人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1458834, encodeId=21c51458834c7, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！, objectType=article, longId=737158, objectId=579ee371587c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=579ee371587c, replyNumber=0, likeNumber=104, createdTime=2022-08-29, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=579ee371587c, moduleTitle=Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=579ee371587c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458833, encodeId=1cb314588331a, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=工程化肿瘤细胞载药系统治疗三阴性乳腺癌肺转移, objectType=article, longId=733415, objectId=bbd5e33415f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbd5e33415f4, replyNumber=0, likeNumber=86, createdTime=2022-07-29, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbd5e33415f4, moduleTitle=工程化肿瘤细胞载药系统治疗三阴性乳腺癌肺转移, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bbd5e33415f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458831, encodeId=bb41145883120, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=Nat Commun：复旦大学王碧芸/胡夕春团队发现转移性三阴性乳腺癌的高效联合化疗方案, objectType=article, longId=733030, objectId=73fbe3303097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73fbe3303097, replyNumber=0, likeNumber=87, createdTime=2022-07-24, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73fbe3303097, moduleTitle=Nat Commun：复旦大学王碧芸/胡夕春团队发现转移性三阴性乳腺癌的高效联合化疗方案, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=73fbe3303097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458830, encodeId=8dcd145883080, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=Ther Adv Med Oncol：洛铂新辅助治疗可改善三阴性乳腺癌患者预后, objectType=article, longId=731076, objectId=fee6e3107677, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fee6e3107677, replyNumber=0, likeNumber=95, createdTime=2022-07-03, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fee6e3107677, moduleTitle=Ther Adv Med Oncol：洛铂新辅助治疗可改善三阴性乳腺癌患者预后, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fee6e3107677)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458832, encodeId=6b1f14588328e, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后, objectType=article, longId=728384, objectId=e24ae28384d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e24ae28384d8, replyNumber=0, likeNumber=91, createdTime=2022-06-02, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e24ae28384d8, moduleTitle=2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e24ae28384d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458829, encodeId=1aad145882927, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=Cancer Res: 化疗联合巨噬细胞抑制三阴性乳腺癌进展, objectType=article, longId=725793, objectId=3613e257935b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3613e257935b, replyNumber=0, likeNumber=86, createdTime=2022-05-01, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3613e257935b, moduleTitle=Cancer Res: 化疗联合巨噬细胞抑制三阴性乳腺癌进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3613e257935b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458828, encodeId=69c6145882857, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=Nature Cancer：LCOR mRNA疗法联合PD-L1抑制剂成功挑战三阴性乳腺癌, objectType=article, longId=723589, objectId=d350e23589a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d350e23589a7, replyNumber=0, likeNumber=84, createdTime=2022-04-07, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d350e23589a7, moduleTitle=Nature Cancer：LCOR mRNA疗法联合PD-L1抑制剂成功挑战三阴性乳腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d350e23589a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458827, encodeId=d8b0145882e32, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=Nature Cancer：免疫疗法+mRNA技术，治疗三阴性乳腺癌并防止复发, objectType=article, longId=301755, objectId=078d301e55cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=078d301e55cd, replyNumber=0, likeNumber=93, createdTime=2022-03-28, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=078d301e55cd, moduleTitle=Nature Cancer：免疫疗法+mRNA技术，治疗三阴性乳腺癌并防止复发, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=078d301e55cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458826, encodeId=63ff145882634, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=Clin Cancer Res：法米替尼、卡瑞利珠单抗和nab-紫杉醇联合治疗晚期三阴性乳腺癌, objectType=article, longId=301566, objectId=a12430156640, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a12430156640, replyNumber=0, likeNumber=91, createdTime=2022-03-25, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a12430156640, moduleTitle=Clin Cancer Res：法米替尼、卡瑞利珠单抗和nab-紫杉醇联合治疗晚期三阴性乳腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a12430156640)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458825, encodeId=caae1458825e2, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=Mol Cancer：新型生物标志物SNORD33可预测三阴性乳腺癌对铂类化疗敏感性, objectType=article, longId=300796, objectId=4279300e9651, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4279300e9651, replyNumber=0, likeNumber=95, createdTime=2022-03-16, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4279300e9651, moduleTitle=Mol Cancer：新型生物标志物SNORD33可预测三阴性乳腺癌对铂类化疗敏感性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4279300e9651)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458824, encodeId=f6d71458824ab, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=PNAS：D-甘露糖通过降解PD-L1促进三阴性乳腺癌的免疫治疗和放疗, objectType=article, longId=300793, objectId=c77e300e932f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c77e300e932f, replyNumber=0, likeNumber=98, createdTime=2022-03-16, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c77e300e932f, moduleTitle=PNAS：D-甘露糖通过降解PD-L1促进三阴性乳腺癌的免疫治疗和放疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c77e300e932f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458823, encodeId=163914588237e, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=Clin Cancer Res：复旦肿瘤晚期免疫调节型三阴性乳腺癌（TNBC）新疗法，有效率高达95.8%, objectType=article, longId=300445, objectId=53d5300445da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53d5300445da, replyNumber=0, likeNumber=90, createdTime=2022-03-12, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53d5300445da, moduleTitle=Clin Cancer Res：复旦肿瘤晚期免疫调节型三阴性乳腺癌（TNBC）新疗法，有效率高达95.8%, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=53d5300445da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458822, encodeId=7676145882247, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=NEJM：手术前后加用派姆单抗可显著提高早期三阴性乳腺癌的生存率, objectType=article, longId=295536, objectId=2e43295536c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e43295536c6, replyNumber=0, likeNumber=0, createdTime=2022-02-14, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e43295536c6, moduleTitle=NEJM：手术前后加用派姆单抗可显著提高早期三阴性乳腺癌的生存率, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2e43295536c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458821, encodeId=9106145882198, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=Cell Research：“高危”三阴性乳腺癌有望增添代谢治疗靶点，“复旦肿瘤”科学家绘制出很大三阴性乳腺癌代谢物图谱, objectType=article, longId=295143, objectId=43a629514382, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43a629514382, replyNumber=0, likeNumber=0, createdTime=2022-02-06, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43a629514382, moduleTitle=Cell Research：“高危”三阴性乳腺癌有望增添代谢治疗靶点，“复旦肿瘤”科学家绘制出很大三阴性乳腺癌代谢物图谱, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=43a629514382)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458820, encodeId=324114588206e, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, objectType=article, longId=294716, objectId=db94294e16ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db94294e16ed, replyNumber=0, likeNumber=109, createdTime=2022-01-27, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db94294e16ed, moduleTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=db94294e16ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458819, encodeId=c8b5145881908, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=J Immunother Cancer：浙大黄建团队提出三阴性乳腺癌肺转移免疫学新机制及其干预策略, objectType=article, longId=265021, objectId=bd0926502166, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd0926502166, replyNumber=0, likeNumber=111, createdTime=2021-12-14, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd0926502166, moduleTitle=J Immunother Cancer：浙大黄建团队提出三阴性乳腺癌肺转移免疫学新机制及其干预策略, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bd0926502166)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458818, encodeId=1faa145881823, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌, objectType=article, longId=221752, objectId=5171221e521f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5171221e521f, replyNumber=0, likeNumber=92, createdTime=2021-12-10, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5171221e521f, moduleTitle=Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5171221e521f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458817, encodeId=4a49145881e7d, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=Cell Metab：“饿死”肿瘤的想法真的可实现了？科学家发现模拟禁食饮食可以阻止三阴性乳腺癌和癌症干细胞逃逸！, objectType=article, longId=219988, objectId=909321998894, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=909321998894, replyNumber=0, likeNumber=97, createdTime=2021-11-10, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=909321998894, moduleTitle=Cell Metab：“饿死”肿瘤的想法真的可实现了？科学家发现模拟禁食饮食可以阻止三阴性乳腺癌和癌症干细胞逃逸！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=909321998894)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458816, encodeId=b42d1458816c7, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=Cancer Cell：张泽民团队等揭示抗PD-L1免疫治疗联合化疗在三阴性乳腺癌中的作用机制, objectType=article, longId=218860, objectId=c4e02188600e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4e02188600e, replyNumber=0, likeNumber=88, createdTime=2021-10-20, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4e02188600e, moduleTitle=Cancer Cell：张泽民团队等揭示抗PD-L1免疫治疗联合化疗在三阴性乳腺癌中的作用机制, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c4e02188600e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1458815, encodeId=5bf51458815f8, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, objectTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, objectType=article, longId=218739, objectId=cba7218e390b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cba7218e390b, replyNumber=0, likeNumber=93, createdTime=2021-10-18, rootId=0, userName=xlysu, userId=a5666112721, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cba7218e390b, moduleTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cba7218e390b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

三阴性

2020-05-29

xlysu (审核中...)

前往app查看评论内容

#三阴性#

Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！

2022-08-29

xlysu (审核中...)

前往app查看评论内容

#三阴性#

工程化肿瘤细胞载药系统治疗三阴性乳腺癌肺转移

2022-07-29

xlysu (审核中...)

前往app查看评论内容

#三阴性#

Nat Commun：复旦大学王碧芸/胡夕春团队发现转移性三阴性乳腺癌的高效联合化疗方案

2022-07-24

xlysu (审核中...)

前往app查看评论内容

#三阴性#

Ther Adv Med Oncol：洛铂新辅助治疗可改善三阴性乳腺癌患者预后

2022-07-03

xlysu (审核中...)

前往app查看评论内容

#三阴性#

2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后

2022-06-02

xlysu (审核中...)

前往app查看评论内容

#三阴性#

Cancer Res: 化疗联合巨噬细胞抑制三阴性乳腺癌进展

2022-05-01

xlysu (审核中...)

前往app查看评论内容

#三阴性#

Nature Cancer：LCOR mRNA疗法联合PD-L1抑制剂成功挑战三阴性乳腺癌

2022-04-07

xlysu (审核中...)

前往app查看评论内容

#三阴性#

Nature Cancer：免疫疗法+mRNA技术，治疗三阴性乳腺癌并防止复发

2022-03-28

一叶知秋 (审核中...)

前往app查看评论内容

#三阴性#

Clin Cancer Res：法米替尼、卡瑞利珠单抗和nab-紫杉醇联合治疗晚期三阴性乳腺癌

2022-03-25

xlysu (审核中...)

前往app查看评论内容

#三阴性#

Mol Cancer：新型生物标志物SNORD33可预测三阴性乳腺癌对铂类化疗敏感性

2022-03-16

xlysu (审核中...)

前往app查看评论内容

#三阴性#

PNAS：D-甘露糖通过降解PD-L1促进三阴性乳腺癌的免疫治疗和放疗

2022-03-16

xlysu (审核中...)

前往app查看评论内容

#三阴性#

Clin Cancer Res：复旦肿瘤晚期免疫调节型三阴性乳腺癌（TNBC）新疗法，有效率高达95.8%

2022-03-12

xlysu (审核中...)

前往app查看评论内容

#三阴性#

NEJM：手术前后加用派姆单抗可显著提高早期三阴性乳腺癌的生存率

2022-02-14

xlysu (审核中...)

前往app查看评论内容

#三阴性#

Cell Research：“高危”三阴性乳腺癌有望增添代谢治疗靶点，“复旦肿瘤”科学家绘制出很大三阴性乳腺癌代谢物图谱

2022-02-06

xlysu (审核中...)

前往app查看评论内容

#三阴性#

J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）

2022-01-27

xlysu (审核中...)

前往app查看评论内容

#三阴性#

J Immunother Cancer：浙大黄建团队提出三阴性乳腺癌肺转移免疫学新机制及其干预策略

2021-12-14

xlysu (审核中...)

前往app查看评论内容

#三阴性#

Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌

2021-12-10

xlysu (审核中...)

前往app查看评论内容

#三阴性#

Cell Metab：“饿死”肿瘤的想法真的可实现了？科学家发现模拟禁食饮食可以阻止三阴性乳腺癌和癌症干细胞逃逸！

2021-11-10

xlysu (审核中...)

前往app查看评论内容

#三阴性#

Cancer Cell：张泽民团队等揭示抗PD-L1免疫治疗联合化疗在三阴性乳腺癌中的作用机制

2021-10-20

xlysu (审核中...)

前往app查看评论内容

#三阴性#

欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见

2021-10-18

科室
- - 订阅+
  - 更多科室
工具
服务